Duality Advisers LP Has $379,000 Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Duality Advisers LP lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 85.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 682 shares of the company’s stock after selling 3,853 shares during the quarter. Duality Advisers LP’s holdings in IDEXX Laboratories were worth $379,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. OFI Invest Asset Management acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $25,000. Valley National Advisers Inc. lifted its stake in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares during the period. Geo Capital Gestora de Recursos Ltd acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $28,000. Covestor Ltd raised its stake in IDEXX Laboratories by 71.8% during the 3rd quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after buying an additional 28 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in IDEXX Laboratories by 108.6% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 73 shares of the company’s stock worth $32,000 after buying an additional 38 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several research analyst reports. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. JPMorgan Chase & Co. raised their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective on the stock. in a research note on Tuesday, January 30th. Barclays raised their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Finally, The Goldman Sachs Group raised their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $591.50.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $489.24 on Friday. The firm has a market cap of $40.63 billion, a price-to-earnings ratio of 48.58, a price-to-earnings-growth ratio of 3.81 and a beta of 1.26. The stock’s 50-day moving average is $532.15 and its 200-day moving average is $510.35. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.05 earnings per share. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,524 shares of company stock valued at $24,871,960. 2.11% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.